Chennai Journal

Ankylosing Spondylitis Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

 Breaking News
  • No posts were found

Ankylosing Spondylitis Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

September 22
22:21 2022
Ankylosing Spondylitis Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
Ankylosing Spondylitis Market
DelveInsight’s ‘Ankylosing Spondylitis (AS)-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the AS, historical and forecasted epidemiology as well as the AS market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

DelveInsight’s ‘Ankylosing Spondylitis (AS)-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the AS, historical and forecasted epidemiology as well as the AS market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The Ankylosing Spondylitis market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM market size from 2019 to 2032. The Report also covers current AS treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Some of the key facts of the Ankylosing Spondylitis Market Report:

  • According to a study by Al-Allaf, Abdul-Wahab (2021), titled, “Audit and Review of Ankylosing Spondylitis Management in Qatar”, out of included 207 AS patients, 70% were males with a male to females ratio of 2.3:1.
  •  As per the DelveInsight estimates, in the US, the total number of diagnosed cases of Allergic rhinitis were around 30 M in 2021 which are expected to grow during the study period, i.e., 2019–2032.
  • As per the DelveInsight estimates, in Germany, the total Age group-specific cases of Allergic rhinitis were around 0.69, 2.4, and 19 M in 2021 for age groups

Key Benefits of the Report:

  • The report covers the descriptive overview of AS, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  •  Comprehensive insight has been provided into the AS epidemiology and treatment.
  •   Additionally, an all-inclusive account of both the current and emerging therapies for AS is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  •  A detailed review of the AS market; historical and forecasted is included in the report, covering the United States drug outreach.

 The report provides an edge while developing business strategies, by understanding trends shaping and driving the United States AS market.

  •  

Got queries? Click here to know more about the Ankylosing Spondylitis  Market Landscape.

Ankylosing Spondylitis Overview

 Ankylosing Spondylitis (AS) also called as Bechterew’s disease is a common inflammatory rheumatic disease that affects the axial skeleton, causing characteristic inflammatory back pain, which can lead to structural and functional impairments and a decrease in quality of life. Clinical features of this group include inflammatory back pain, asymmetrical peripheral oligoarthritis (predominantly of the lower limbs), enthesitis, and specific organ involvement such as anterior uveitis, psoriasis, and chronic inflammatory bowel disease. Aortic root involvement and conduction abnormalities are rare complications of AS. AS affects men more often than women. 

 

General onset of AS commonly occurs in younger people, between the ages of 17 and 45. 

 

However, it can also affect children and those who are much older (Spondylitis association of america).AS is a type of spondyloarthropathy (SpA)—Spondyloarthropathies are a family of related inflammatory rheumatic disorders which also include reactive arthritis (RA), psoriatic arthritis (PsA), spondyloarthropathy associated with inflammatory bowel disease (IBD), undifferentiated spondyloarthropathy (USpA), and, possibly, Whipple disease and Behçet disease—and is often found in association with other spondyloarthropathies, including ReA, PsA, ulcerative colitis (UC), and Crohn disease. It has also been found that such patients quite often have a family history of either AS or another spondyloarthropathy. 

 

The most commonly used criteria for the classification of AS were developed in 1966 and modified in 1984. They are:

 

1 Low back pain of at least three months duration with inflammatory characteristics (improved by exercise, not relieved by rest)

2 Limitation of lumbar spine motion in sagittal and frontal planes

3 Decreased chest expansion (relative to normal values for age and sex)

4 Bilateral sacroiliitis grade 2 or higher

5 Unilateral sacroiliitis grade 3 or higher.

 

Treatment of Ankylosing spondylitis will depend on the symptoms, age, and general health. It will also depend on how severe the condition is. The treatment goal is to reduce pain and stiffness, prevent deformities, and maintain as normal lifestyle as possible. Treatment may include: Nonsteroidal anti-inflammatory medications to reduce pain and inflammation, tumor-necrosis-factor blockers (biologic medications) to reduce inflammation and swelling, disease-modifying antirheumatic drugs (DMARDs) such as sulfasalazine to decrease inflammation and control AS, short-term use of corticosteroids to reduce inflammation, short-term use of muscle relaxants and pain relievers to relieve severe pain and muscle spasms, surgery to replace a joint, place rods in the spine, or remove parts of the thickened and hardened bone. Moreover, maintaining proper posture and regular exercise, including exercises that strengthen back muscles.

 

 Ankylosing Spondylitis Epidemiological Insight

 

  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent cases of Ankylosing Spondylitis, Diagnosed Prevalent cases of Ankylosing Spondylitis, Gender-specific Diagnosed Prevalent cases of Ankylosing Spondylitis, Age-specific Diagnosed Prevalent cases of Ankylosing Spondylitis, and Gene-specific Diagnosed Prevalent cases of Ankylosing Spondylitis scenario in the 7MM countries from 2019 to 2032.
  • As mentioned in a study conducted by Alam Fiaz et al. (2017), titled, “Characteristics of Ankylosing Spondylitis patients living in Qatar”, the male to female ratio for Ankylosing spondylitis was found to be 5.2:1
  •  A study by Abdelrahman M. H. et al. (2012), states
  • that the prevalence of HLA-B27 among AS patients in the Arab world is generally lower than the worldwide figure, ranging from 56 to 84%: 84% in Iraq, 56% in UAE, 67% in Saudi Arabia, 58.6% in Egypt, 60% in Syria, and 73.4% in Iran.

 

Ankylosing Spondylitis Epidemiological Segmentation 

  • Total Prevalent cases of Ankylosing Spondylitis in the GCC 
  • Diagnosed Prevalent cases of Ankylosing Spondylitis in the GCC
  • Age-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in the GCC
  • Gender-specific Diagnosed Prevalent cases of Ankylosing Spondylitis in the GCC

Ankylosing Spondylitis Market Outlook 

Ankylosing spondylitis (AS) is an inflammatory disease that, over time, can cause some of the small bones in the spine (vertebrae) to fuse. This fusing makes the spine less flexible and can result in a hunched-forward posture. If ribs are affected, it can be difficult to breathe deeply. There is no cure for AS, but treatments can lessen your symptoms and possibly slow progression of the disease. Recent studies show that the newer biologic medications can potentially slow disease progression in some people. Different people respond to different medications with varying levels of effectiveness. Thus, it may take time to find the most effective course of treatment.

 

A common treatment regimen for the various forms of spondyloarthritis (AS, psoriatic arthritis, enteropathic arthritis, reactive arthritis, juvenile spondyloarthritis, and undifferentiated spondyloarthritis) involves medication, exercise, physical therapy, good posture practices, and other options such as applying heat/cold to help relax muscles and reduce joint pain. In severe cases, posture correcting surgery may also be an option.

 

Depending on the type of spondyloarthritis, there may be some variation in treatment. For example, in psoriatic arthritis, both the skin component and joint component must be treated. In enteropathic arthritis (spondylitis/arthritis associated with inflammatory bowel disease), medications may need to be adjusted so the gastrointestinal component of the disease is also treated and not exacerbated. 

 

As per the study conducted by Ward et al., (2019), recommendations for AS and non radiographic axial SpA are similar. TNFi are recommended over secukinumab or ixekizumab as the first biologic to be used. Secukinumab or ixekizumab is recommended over the use of a second TNFi in patients with primary nonresponse to the first TNFi. TNFi, secukinumab, and ixekizumab are favored over tofacitinib. Co‐administration of low‐dose methotrexate with TNFi is not recommended, nor is a strict treat‐to‐target strategy or discontinuation or tapering of biologics in patients with stable disease. Sulfasalazine is recommended only for persistent peripheral arthritis when TNFi are contraindicated.

 

Of the patients included in the study, 40.6% persisted on the index TNFi for ≥12 months, 31.0% discontinued, 21.4% switched to a different TNFi, and 7.0% discontinued and then restarted. Of the 333 patients who persisted on their TNFi for >90 days, 44.7% received ≥1 add-on medication. Approximately half of the patients (45.1%) initiated etanercept, followed by adalimumab (28.6%), golimumab (11.7%), infliximab (11.7%), and certolizumab pegol (2.8%) as their index TNFi was stated in a study conducted by Walsh et al., (2018).

 

Learn more by requesting for sample @AnkylosingSpondylitisMarket Landscape

 

 Ankylosing Spondylitis Key Companies

  • UCB Biopharma 
  • Celgene  

 

Ankylosing Spondylitis Therapies

  • Bimekizumab
  • 2CC-99677

 

Table of Contents

  •  Key Insights 
  •  Report Introduction 
  •  Executive Summary of Ankylosing Spondylitis
  •  Disease Background and Overview
  •  Epidemiology and patient population
  • The United States 
  •  EU 5
  •  Ankylosing Spondylitis  Emerging Therapies
  • Ankylosing Spondylitis Market Outlook
  • Market Access and Reimbursement of Therapie
  •  Appendix
  •   Ankylosing Spondylitis Report Methodology
  •   DelveInsight Capabilities
  •   Disclaimer
  •  About DelveInsight

Click here to read more about Ankylosing Spondylitis market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles